ExonHit still looking to buy after termination of RedPath deal
This article was originally published in Clinica
Executive Summary
French diagnostics firm ExonHit Therapeutics is on the acquisition trail after it cancelled its proposed purchase of DNA-based tests specialist RedPath Integrated Pathology. ExonHit said that it still intends to acquire a revenue-generating molecular diagnostics company in order to develop its external growth.